Table 3. Efficacy outcomes of apatinib-treated patients with primary lung cancer grouped by their different histologies and cavitation statuses.

Outcome	6-month PFS rate (%)						HR (95% CI)
	SCC			Adenocarcinoma			Cavitation effect#			Histology effect†
	Cavitation−	Cavitation+		Cavitation−	Cavitation+		SCC	Adenocarcinoma		Cavitation−	Cavitation+
LRC	40	92.3		5.4	75		0.085** (0.021 to 0.338), P<0.001	0.020* (0.001 to 0.383), P=0.009		0.970 (0.431 to 2.179), P=0.940	0.436 (0.171 to 1.114), P=0.083
PFS	20	92.3		5.4	75		0.165* (0.054 to 0.505), P=0.002	0.020* (0.001 to 0.383), P=0.009		0.970 (0.431 to 2.179), P=0.940	0.573 (0.240 to 1.369), P=0.210
OS	73.3	92.3		53.2	100		0.111* (0.028 to 0.443), P=0.002	0.358 (0.125 to 1.024), P=0.055		0.635 (0.238 to 1.696), P=0.940	0.987 (0.298 to 3.263), P=0.983

*, P<0.05; **, P<0.01; ^#, evaluation of the effect of treatment in different cavitation status. HR <1 favored cavitation formed; ^†, evaluation of the effect of treatment in different tumor types. HR <1 favored adenocarcinoma histology. PFS, progression-free survival; HR, hazard ratio; LRC, locoregional control in lung herein; OS, overall survival.